CD163 and melanoma: A recent study demonstrated that the specific targeting of a subset of M2-TAMs expressing CD163 induced tumor regression in a murine melanoma model (C57BL/6J mice subcutaneously injected with the anti-PD-1 resistant YUMM1.7 cell line).